The National Agency for Food and Drug Administration and Control (NAFDAC) has officially blacklisted ACME Healthcare Limited, located at No. 3 Church Street, Lakowe Phase 2, Lekki Expressway, Lagos, as well as anywhere else the company operates. This action is a result of serious regulatory violations, including the unauthorized importation and distribution of several products: A-Tocin injection, Extocin injection, Claxitodin injection, and Gold Vision Oxytocin injection, all manufactured by Anhui Hongye Pharmaceutical Co., Ltd in China, as well as Acmequin (Chloroquine Phosphate Injection 40mg/ml) NAFDAC REG. NUMBER: B4-1811, manufactured by NITIN LIFESCIENCE LTD, Rampur Rd, Paonta Sahib District, India.
The company was found to be using registration numbers such as B4-2006, A4-9566, and B4: 1811 without proper authorization.
Please note that the NRN: B4-2006 belongs to Cimapro-500(Ciprofloxacine tablet 500mg) registered by ACME Healthcare Ltd. Furthermore, ACME Healthcare Limited has several products registered by the agency, but only one currently has a valid license.
The MD was contacted by phone at 07037092255 in 2024 to report for a consultative meeting, but he refused to attend and has blocked all lines used to reach him.
NAFDAC’s blacklisting mechanism serves to shield public health by:
- Prohibiting the sale, distribution, or use of all products associated with the erring firm.
- Alerting healthcare providers and consumers to potential safety hazards.
For ACME Healthcare Ltd, blacklisting entails:
- Immediate cessation of all product marketing and importation activities.
- Potential prosecution for offenses under the NAFDAC laws and regulations.
All NAFDAC zonal directors and state coordinators have been directed to conduct surveillance and mop up substandard/falsified products within their zones and states.
NAFDAC implores distributors, suppliers, wholesalers, healthcare providers, and patients to exercise caution and vigilance within the supply chain to avoid distribution, sale, administration, and use of the products marketed by ACME Healthcare Ltd. All medical products must be obtained from genuinely authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked.
If you have any product marked by ACME Healthcare Ltd, please stop selling or using them immediately and submit your stock to the nearest NAFDAC office. If you or someone you know has used any products marketed by the company, or if you have experienced negative reactions or events, we strongly recommend seeking immediate medical advice from a qualified healthcare professional.
Healthcare professionals and consumers are advised to report any suspicion of substandard and falsified medicines to the nearest NAFDAC office, NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng
Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of the medicinal product to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng, or via the Med-safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng
Thank you.
Prof. Mojisola Christianah Adeyeye FAS
Director General
